Hana Pharm is a pharmaceutical company that makes and sells prescription drugs, which require a doctor's prescription. It has long held a leading domestic position in narcotic painkillers and surgical anesthetics, areas with high regulatory barriers that make it hard for new entrants, and it spreads its revenue across roughly 380 products so it is not overly reliant on any single line. Filings in February 2026 confirmed annual revenue of ₩239.5 billion, operating profit of ₩25.8 billion, and net profit of ₩8.8 billion, and first-quarter net profit swung back up into three digits, signaling a recovery in earnings. What stands out recently is that the more this first-quarter earnings inflection is confirmed in the full-year figures, the more appealing its double-digit operating margin, nearly debt-free balance sheet, and low valuation at a P/B of 0.47x become; but the appeal fades if the earnings recovery lasts only a quarter or two, or if the one-off items that weighed on last year's net profit recur.
At-a-glance assessment financial health · growth · profitability · valuation
- Debt ratio, current ratio and interest burden all look healthy.
- Revenue rose 6.3% year over year, and the pace is quickening (3-year trend: rising).
- Most recent quarter (Q1 2026) revenue was 8.3% higher than a year earlier.
- ROE is 2.8% (total-net basis). It is below the sector average.
- Operating margin is 10.8%.
- P/B is low versus peers too, so it looks cheap on an asset basis as well.
Ownership & governance As of 2025-12-31
Largest shareholder Cho Dong-hoon 25.29% (individual)
Controlling bloc incl. related parties 57.72%
With the controlling bloc holding 58%, control is very secure but the free float is thin.
🔎 In-depth analysis
- Hana Pharm makes and sells prescription drugs, medicines that require a doctor's prescription.
- It has long held a leading domestic position in narcotic painkillers used for severe pain and in surgical anesthetics, and a key strength here is that these fields carry strict licensing and control regulations that make it hard for new companies to enter.
- On top of this, it carries roughly 380 products across cardiovascular, analgesic, digestive, neurology, and dermatology categories, giving it a revenue structure that is not skewed toward any single area.
- Because its market capitalization is not large, a single earnings trend or filing tends to have a relatively big effect on the share price.
- The latest close is ₩8,410 and the market cap is ₩149.5 billion.
- The price sits below both the 20-day line (₩8,810) and the 60-day line (₩9,329).
- Trading below both the short- and mid-term moving averages, the trend is on the soft side.
- The RSI (a supplementary gauge that measures upward versus downward momentum over the past 14 days on a 0-100 scale) is 36.7, a neutral level.
- The price is down 5.8% over one month and down 8.4% over three months, and sits 32.2% below its 52-week high.
- Its relative strength versus the KOSPI is 8 (on a 1-99 scale that converts the past year's return against the index, weighted toward the recent period; higher means stronger than the market).
- That places it in roughly the top 93% of all stocks by strength.
- Over the past three months it lagged the index by 26.9%.
- It is best to read the chart alongside trading volume and disclosure dates.
- Recent annual revenue is ₩239.5 billion, with operating profit of ₩25.8 billion and net profit of ₩8.8 billion.
- The operating margin is a solid 10.8%, and with a debt ratio (debt to equity) of 33.4%, a current ratio of 184%, and an interest coverage ratio of 71x, the balance sheet is stable with almost no debt burden.
- The P/B (share price to book value) is 0.48x, less than half of book value, and with a payout ratio of 52% and a dividend yield of about 3.1%, shareholder returns are steady.
- The headline P/E (share price to one year of earnings) of 17.03x looks ordinary, but it is based on the prior year's results, in which net profit was temporarily depressed by one-off items.
- In an inflection phase where earnings are turning back up, the forward P/E, which reflects future earnings, is closer to the real picture than the headline P/E, and it is clearly lower than the peer group.
- Revenue rose steadily from ₩196.4 billion in 2021 to ₩239.5 billion in 2025, and the pace of growth has gradually quickened (an uptrend over three years).
- The key is the turn in earnings direction.
- First-quarter 2026 revenue was ₩62.3 billion, up 8.3% year on year, while operating profit rose 26.2% to ₩7.1 billion and net profit jumped 135.9% to ₩10.0 billion.
- A single quarter's net profit (₩10.0 billion) has already exceeded the prior full year's net profit (₩8.8 billion), showing that the one-off burdens that weighed on last year have lifted and the underlying earnings power is returning.
- Steady demand in high-barrier core products such as narcotic painkillers and anesthetics provides support, and with the operating margin holding in double digits, the projected recovery to ₩38.2 billion in net profit and ₩27.1 billion in operating profit this year has grounding in the quarterly results.
- The forward P/E reflects this recovered level of earnings.
- Recent filings cluster around the recovery and shareholder returns.
- On April 20, 2026, the company voluntarily disclosed a corporate value-up plan, setting out its own direction for enhancing value, and on February 3 an earnings-structure change filing confirmed annual revenue of ₩239.5 billion, operating profit of ₩25.8 billion, and net profit of ₩8.8 billion.
- The January 26 report on the results of a treasury-share disposal is a filing tied to cash returns and changes in share count; such materials are best read together with whether earnings power and cash flow provide backing.
- The strengths are clear.
- Holding a leading position in the high-barrier fields of narcotic painkillers and anesthetics, it maintains a double-digit operating margin and a nearly debt-free balance sheet, and in the first quarter of 2026 net profit rose into three digits as earnings turned back up.
- As a result it sits at a low valuation of 0.47x P/B, a level that makes it hard to call the stock expensive on headline metrics alone.
- Points to watch are whether the earnings recovery continues through the full year rather than just a quarter or two, and whether the one-off items that weighed on last year's net profit stay away.
- In short, the more the earnings inflection seen in the first quarter is confirmed in the full-year results, the more the appeal of the low valuation comes alive; if the recovery proves to be a temporary effect, that appeal diminishes.
🔎 Valuation vs peers Undervalued
A peer group of pharmaceutical and biotech names with adjacent market capitalizations.
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Kyung Dong Pharm | 17.97x | 0.67x | 3.73% |
| Ilyang Pharmaceutical | 23.00x | 0.67x | 2.91% |
| CMG Pharma | — | 0.64x | -5.00% |
Within pharma and biotech, we first looked at a public-data peer group with nearby market capitalizations. The current P/E (share price to one year of earnings) is 17.03x and the P/B (share price to book value) is 0.48x. That said, because smaller-cap names are heavily affected by earnings swings and financing filings, we did not draw firm conclusions from metrics based on last year's confirmed results alone. The basis for the outlook box is a DART seasonality approximation.
Earnings outlook company-stated · verified
| Type | Period | Revenue | Operating profit | Net profit |
|---|---|---|---|---|
| This year | 2026 | ₩254.4 billion | ₩27.1 billion | ₩38.2 billion |
| Next quarter | Q2 2026 | ₩62.3 billion | ₩6.6 billion | ₩11.1 billion |
Price history Close · MA20 · MA60
The latest close is ₩8,410 and the market capitalization is ₩149.5 billion. The price sits below its 20-day moving average (₩8,810) and below its 60-day moving average (₩9,329). It is under both its short- and medium-term moving averages, so the trend looks subdued. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 36.7, a neutral level. The one-month change is -5.8%, the three-month change is -8.4%, and the position relative to the 52-week high is -32.2%. Relative strength versus the KOSPI is 8 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 7% of all stocks. Over the past three months it lagged the index by 26.9%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
Relative performance stock vs index · start = 100
Excess return vs index · 3M -26.94% / 6M -52.12% / 12M -70.87%
Key metrics vs sector median
Valuation
The P/E of 17.03x is in line with the sector median (15.98x). The P/B of 0.48x is below the sector median (1.37x). That said, this P/E is based on last year's (trailing) results. With recent quarterly earnings up sharply, the trailing P/E can look higher than it really is, so a precise read is best done on this year's expected (forward) earnings.
Enterprise value (EV)
EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.
Profitability & financials
Return on equity (ROE) is 2.8%, in line with the sector average (3.0%). The operating margin is 10.8%. The debt ratio is 33.4%, so the financial structure is stable.
Growth FY2025 · annual report (separate)
| Item | 2023 | 2024 | 2025 | YoY |
|---|---|---|---|---|
| Revenue | $148.8M | $149.3M | $158.7M | +6.29% ↑ faster |
| Operating profit | $17.9M | $16.7M | $17.1M | +2.63% ↑ faster |
| Net profit | $14.8M | $14.1M | $5.8M | -58.69% ↓ slower |
| 5-year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $130.2M | $139.7M | $148.8M | $149.3M | $158.7M |
| Operating profit | $23.9M | $20.7M | $17.9M | $16.7M | $17.1M |
| Net profit | $18.6M | $16.1M | $14.8M | $14.1M | $5.8M |
| Revenue CAGR | 4-yr avg 5.08% | ||||
Revenue rose 6.3% year over year (2023 ₩224.5 billion → 2024 ₩225.3 billion → 2025 ₩239.5 billion), and the three-year trend is 'rising'. The pace of growth also quickened from the prior year. Operating profit rose 2.6% year over year. Profit is growing at an accelerating pace. Over the 5 years on record, revenue compound annual growth (CAGR) is 5.1%. The two-year revenue CAGR is 3.3%. In the most recent quarter (Q1 2026), revenue was 8.3% higher than the same period a year earlier.
Latest quarterly results Q1 2026 · vs year-ago
Technical indicators
What stands out
- P/E and P/B are both low versus peers, so the price looks inexpensive relative to earnings and assets.
- The dividend yield, at 3.1%, is on the high side.
- The balance sheet is stable in terms of debt and liquidity.
Points to watch
- The figures shown are based on the last annual report as of the writing date, so it is best to review the latest quarterly results and filings alongside them.
Recent news & events searched · sourced
- 2026-04-20UpdateCorporate value-up plan (voluntary disclosure): see the original company plan.This is a planning document the company presented itself. If it contains figures, treat it as a primary basis for the outlook box; if not, read it only as an indication of direction. Source
- 2026-02-03EarningsChange in revenue or profit structure of 30% or more (15% for large corporations): annual revenue ₩239.5 billion, operating profit ₩25.8 billion, net profit ₩8.8 billion.This is recent confirmed or provisional earnings data. Check whether it points in the same direction as the annual trend and whether any one-off factors are present. Source
- 2026-01-26UpdateReport on the results of a treasury-share disposal: check the terms of the return.This is a filing related to cash returns or changes in share count. Check whether earnings power and cash flow provide backing. Source
Figure cross-check computed ↔ external
| Metric | Computed | External | Status | Source |
|---|---|---|---|---|
| Closing price | ₩8,410 | ₩8,410 | Confirmed | link |
| Latest quarterly results | revenue ₩62.3 billion, operating profit ₩7.1 billion | revenue ₩62.3 billion, operating profit ₩7.1 billion | Confirmed | link |
| Annual results | revenue ₩239.5 billion, operating profit ₩25.8 billion | revenue ₩239.5 billion, operating profit ₩25.8 billion | Confirmed | link |
| Original outlook/plan filing | : | : | Confirmed | link |
| Original earnings filing | revenue30%: revenue ₩239.5 billion · operating profit ₩25.8 billion · net profit ₩8.8 billion | revenue30%: revenue ₩239.5 billion · operating profit ₩25.8 billion · net profit ₩8.8 billion | Confirmed | link |
| Original shareholder-return filing | : | : | Confirmed | link |
| Outlook box basis | DART | DART | Confirmed | link |
Recent filings
- 2026-06-02OwnershipLargest-shareholder ownership change report
- 2026-06-02OwnershipOfficers'/major-shareholders' holdings report
- 2026-06-02OwnershipOfficers'/major-shareholders' holdings report
- 2026-06-01Corporate governance report
- 2026-05-15PeriodicQuarterly report
- 2026-04-20Disclosure
- 2026-03-30Shareholders' meeting notice
- 2026-03-20PeriodicAnnual business report
- 2026-03-20Audit report
- 2026-03-13Shareholders' meeting notice
- 2026-03-13Shareholders' meeting notice
- 2026-03-13Amended filing
📖 Plain-language glossary — expand if you are new to this
- P/E
- How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
- P/B
- Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
- P/S
- Price relative to a year's revenue — useful for growth companies with thin earnings.
- Net debt / EV
- Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
- EV/EBIT · EV/EBITDA · EV/Sales
- Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
- FCF / FCF yield
- Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
- Intrinsic value (DCF)
- Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
- ROE
- How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
- EPS / BPS
- Earnings per share / net assets (book value) per share.
- Operating / net margin
- Profit left from the core business / final profit after tax and interest, per unit of revenue.
- Debt ratio
- Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
- Current ratio
- Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
- Interest coverage
- How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
- Dividend yield / payout ratio
- The year's dividend as a % of today's price / the share of earnings paid out as dividends.
- Revenue CAGR
- Multi-year growth expressed as a single yearly average (compound annual growth rate).
- RSI (short-term signal)
- Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
- MA20 / MA60 (moving averages)
- The 20- and 60-day average price. Price above them signals a firmer short-term trend.
- vs 52-week high
- How far below the past year's peak the price sits now (%).
All figures are for reference only; how they read varies by sector and over time.
Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.
Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.